<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03977090</url>
  </required_header>
  <id_info>
    <org_study_id>Gxplore-012-1</org_study_id>
    <nct_id>NCT03977090</nct_id>
  </id_info>
  <brief_title>Genolimzumab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer</brief_title>
  <official_title>Phase Ib Clinical Trial of Genolimzumab Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genor Biopharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hutchison Medipharma Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Genor Biopharma Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, dose-escalating phase Ib clinical study to evaluate the safety
      and tolerability of GB226 in combination with fruquintinib in the treatment of mCRC, evaluate
      the pharmacokinetic characteristics of GB226 in combined therapy, evaluate immunogenicity of
      GB226, and explore the antitumor activity of GB226 in combination with fruquintinib in the
      treatment of mCRC.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 4, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>Adverse Event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Limited Toxicity,DLT</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>To evaluate the safety of GB226 as defined by dose limited toxicity in patients with metastatic colorectal cancer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Extended period recommended dose,RDE</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>To evaluate the safety of GB226 as defined by extended period recommended dose in patients with metastatic colorectal cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>T max</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>T max</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C max</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>C max</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C ss,min</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>C ss,min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R C,trough</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>R C,trough</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate, ORR</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>To evaluate the efficacy of GB226 as defined by objective response rate in patients with metastatic colorectal cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>To evaluate the efficacy of GB226 as defined by overall response rate, in patients with metastatic colorectal cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response, DOR</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>To evaluate the duration of response (DOR) of GB242 in patients with metastatic colorectal cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival, PFS</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>To evaluate the efficacy of GB226 as defined by progression-free survival in patients with metastatic colorectal cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival, OS</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>To evaluate the duration from the first administration to death because of any reason in patients with metastatic colorectal cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antidrug antibody, ADA</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>Antidrug antibody, ADA</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>GB226+Fruquintinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Geptanolimab combined with Fruquintinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Geptanolimab Injection</intervention_name>
    <description>GB226 3mg/kg, q2w, iv.</description>
    <arm_group_label>GB226+Fruquintinib</arm_group_label>
    <other_name>Recombinant humanized anti-PD-1 monoclonal antibody injection</other_name>
    <other_name>Geptanolimab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fruquintinib</intervention_name>
    <description>Fruquintinib 3 or 4 or 5mg,qd,po. 3 weeks-on, 1 week-off</description>
    <arm_group_label>GB226+Fruquintinib</arm_group_label>
    <other_name>HMPL-013</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients who meet the following criteria can be enrolled in this study:

          1. Aged 18 to 75 years, males or females;

          2. Understand the study procedures and contents, and voluntarily sign the written
             informed consent form;

          3. Patients with histologically/pathologically confirmed colorectal cancer;

          4. Patients with metastatic colorectal cancer, who failed to respond to the previous
             first-line treatment or above. Treatment failure refers to disease progression or
             intolerable toxicity after ≥1 cycle of treatment, or relapse during adjuvant or
             neoadjuvant chemotherapies period or within 6 months after the end of treatment;

          5. ECOG score of 0-1;

          6. Life expectancy≥3 months;

          7. There is at least one measurable and evaluable tumor lesion (in accordance with
             RECIST1.1 criteria);

          8. Systemic chemotherapy, targeted therapies or other anti-tumor biotherapy (tumor
             vaccine, cytokine or growth factor aimed at controlling tumor) are completed at least
             4 weeks before the first dose of investigational product (the oral fluorouracil is
             discontinued at least 2 weeks ago); systemic or local palliative radiotherapy is
             completed at least 4 weeks ago; no anti-angiogenic small molecular target drugs are
             previously received;

          9. Systemic corticosteroids (prednisone &gt; 10mg/day or equivalent dose) is discontinued at
             least 2 weeks before the use of the first investigational product;

         10. The major surgery requiring general anesthesia must be completed at least 8 weeks
             before the use of the first investigational product; surgery requiring local
             anesthesia/epidural anesthesia must be completed at least 4 weeks before the use of
             the first investigational product;

         11. Routine blood tests require hemoglobin (HGB) ≥90g/L (no transfusion is allowed within
             14 days before routine blood tests at baseline), neutrophil count (ANC)≥1.5×109/L
             (received no supportive treatment with recombinant human granulocyte colony
             stimulating factor within 14 days before routine blood tests at baseline), platelet
             ≥100×109/L (received no supportive treatment such as recombinant human thrombopoietin
             (TPO) or transfusion within 14 days before routine blood tests at baseline);

         12. Serum creatinine ≤ 1.5×ULN or creatinine clearance ≥ 60 mL/min (calculated based on
             Cockcroft-Gault formula), and urinary protein ˂ 2+ or ˂1.0g/L; For patients with
             baseline urinary protein ≥ 2+ or ≥ 1.0g/L, quantitative test of 24h urinary protein
             will be performed and will be enrolled only when the result ≤ 1.0g/L is obtained.

         13. Total bilirubin ≤1.5×ULN (unless it is confirmed to have Gilbert's Syndrome),
             aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN (AST
             and/or ALT≤5×ULN is allowed for patients with hepatic metastasis);

         14. Thyroid function variables: thyroid-stimulating hormone (TSH) and free thyroxine
             (FT3/FT4) are within the normal range; if TSH is not within the normal range, but
             FT3/FT4 is within the normal range, the subjects can be enrolled.

         15. The adverse reactions caused by the previous treatment should recover to grade 1 and
             below before enrollment (except alopecia and ≤ grade 2 neurological toxicity caused by
             chemotherapy drugs);

         16. Female subjects who are confirmed not pregnant within 7 days before administration;
             males or females should agree to adopt medically confirmed effective contraceptive
             measures during the entire study period and within 6 months after the end of this
             study.

         17. Patients can receive follow-up visits as scheduled, well communicate with the
             investigators and complete the study as required by the study.

        Exclusion Criteria:

        Any patient fulfilling any of the following exclusion criteria is excluded from this study:

          1. Active central nervous system (CNS) metastasis, including symptomatic brain metastasis
             or meningeal metastasis or spinal cord compression etc.; subjects with asymptomatic
             brain metastasis (no progression within at least 4 weeks after radiotherapy and/or no
             neurological symptom or sign after surgical resection, treatment with glucocorticoids,
             antiepileptic drugs, anticonvulsants or mannitol is not necessary) can be enrolled;

          2. Patients who previously had other malignant tumors (excluding cured cervical carcinoma
             in situ and skin basal cell carcinoma) are not allowed to participate in the study
             unless he/she completely relieved at least 2 years before enrollment and requires no
             other treatment now or during the study period.

          3. Medical history of active, known autoimmune diseases, including but not limited to
             systemic lupus erythematosus, psoriasis, rheumatoid arthritis, inflammatory
             gastrointestinal disorders, Hashimoto's thyroiditis etc. The following should be
             excluded: type I diabetes mellitus, hypothyroidism which can be controlled by hormone
             replacement therapies only, skin diseases requiring no systemic treatment (e.g.,
             vitiligo, psoriasis) and controlled celiac disease;

          4. Patients who are previously treated with anti PD-1 antibody, anti PD-L1 antibody, anti
             PD-L2 antibody or anti CTLA-4 antibody (or any other antibodies acting on T cell
             co-stimulation or checkpoint pathway);

          5. Uncontrolled hypertension ( systolic blood pressure ≥140mmHg and/or diastolic blood
             pressure ≥90mmHg) or pulmonary arterial hypertension or unstable angina pectoris;
             previous presence of myocardial infarction or received coronary artery bypass grafting
             or coronary stent implantation within 6 months before administration; medical history
             of chronic heart failure NYHA (New York Heart Association) class 3 and 4; clinically
             significant valvular heart diseases; subjects with serious arrhythmia requiring
             treatment, including QTc interval ≥450ms for males and ≥470ms for females (calculated
             based on Fridericia formula); cerebrovascular accident (CVA) or transient ischemic
             attack (TIA) within 12 months before administration;

          6. Patients who have medical history of arterial thrombosis or deep vein thrombosis
             within 6 months before the first dose of investigational product, or patients who have
             evidence or medical history of bleeding tendency within 2 months before the first dose
             of investigational product, regardless of severity; activated partial thromboplastin
             time (APTT) or prothrombin time (PT) &gt;1.5×ULN;

          7. The skin wounds, surgery site, trauma site, serious mucosal ulcer or facture are not
             completely healed.

          8. The imaging tests showing the evidence of tumor invasion to large vessels, including
             tumors which are completely close to, surround or invade to internal cavity of large
             vessels (e.g., pulmonary artery or superior vena cava);

          9. Patients with dysphagia or known drug malabsorption;

         10. Gastrointestinal disorder which may significantly affect absorption of oral drugs or
             other conditions which may affect gastrointestinal hemorrhage or perforation (e.g.,
             duodenal ulcer, bowel obstruction, acute Crohn's disease, ulcerative colitis,
             resection of large area of stomach and small intestine etc.) at the discretion of the
             investigators; Patients who have chronic Crohn's disease and ulcerative colitis
             (excluding patients with resection of entire colon and rectum), even in non-active
             stage, should be excluded. Patients with hereditary nonpolyposis colorectal cancer or
             familial adenomatous polyposis syndrome; Previous medical history of intestinal
             perforation, intestinal fistula, which is not cured after surgical treatment;

         11. Subjects with current or previous interstitial lung pneumonia;

         12. Uncontrolled pleural, peritoneal and pericardial effusion requiring repeated drainage
             or showing significant symptoms;

         13. Patients with active infection requiring systemic treatment; active pulmonary
             tuberculosis (TB) infection;

         14. Positive human immunodeficiency virus antibody (HIV-Ab); active syphilis; positive
             hepatitis C antibody (HCV-Ab) and HCV-RNA&gt; the upper limit of normal of the test
             units; positive hepatitis B surface antigen (HBsAg) and HBV-DNA copies &gt; the upper
             limit of normal of the test units;

         15. Patients with complications requiring treatment with immunosuppressive drugs or
             systemic or local corticosteroids at the immunosuppressive doses (prednisone &gt;
             10mg/day or equivalent dose of similar agents);

         16. It is expected that live vaccines or attenuated vaccines are given 4 weeks before the
             use of investigational drug, during treatment period or within 5 months after the last
             dose;

         17. Subjects who have medical history of drug addiction or drug abuse;

         18. Lactating women (subjects who agree to stop breastfeeding during the study period can
             be enrolled);

         19. Patients who received other investigationsl drugs within 30 days before the use of
             investigational drug or within 5 half-lives of other investigational drugs (whichever
             is shorter) or used investigational medical device within 30 days;

         20. Subjects who are known to be allergic to investigational product or any of its
             excipients; subjects who are known to have medical history of allergic diseases;

         21. Subjects who are considered unsuitable for participating in this study at the
             discretion of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuxian Bai</last_name>
    <role>Principal Investigator</role>
    <affiliation>Affiliated tumor hospital of Harbin medical university</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shawn Yu, Master</last_name>
    <phone>86-010-85260820</phone>
    <email>shawn.yu@genorbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuxian Bai, Doctor</last_name>
      <phone>86 13945095085</phone>
      <email>bai_yuxian@126.com</email>
    </contact>
    <investigator>
      <last_name>Yuxian Bai, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 24, 2019</study_first_submitted>
  <study_first_submitted_qc>June 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

